However, our study was able to detect several candidate biomarkers with significant variability despite the small sample size, and among them, SFTPB in serum EVs was verified to be associated with ILD progression using validation cohorts and experiments of human samples and a mouse model. Here, SFTPB is linked to interstitial lung disease.